Cancer that has spread to the brain can be treated — and modern care does far more than whole-brain radiation. CION's neuro-oncology tumour board builds one joined-up plan: precise radiosurgery, coordinated surgery when needed, and systemic therapy matched to your primary cancer.
Brain metastases are secondary brain tumours: cancer that started somewhere else in the body and has spread to the brain. They are far more common than primary brain tumours. Hearing that cancer has reached the brain is frightening — but it does not mean nothing can be done. For many people, the right plan controls the lesions, protects brain function, and keeps the original cancer in check.
Treatment today is rarely "just whole-brain radiation." A modern plan usually combines stereotactic radiosurgery for a limited number of lesions, surgery for selected cases, whole-brain radiation when needed, and systemic therapy matched to the primary cancer. At CION, every case is reviewed by a neuro-oncology tumour board so these pieces fit together. This page explains each option and how the plan is chosen. For the full picture of brain-tumour care, see our Brain Cancer & Tumour hub and our brain tumor treatment in Hyderabad overview.
Modern guidelines from the NCCN and the European Association of Neuro-Oncology (EANO) now favour stereotactic radiosurgery over whole-brain radiation for patients with a limited number of brain metastases, because focused radiosurgery treats only the lesions and preserves memory and thinking far better. Some centres now treat ten or more lesions with radiosurgery rather than irradiating the whole brain.
A brain metastasis is treated differently from a tumour that started in the brain. The brain lesions are targeted, but the biology of your original cancer drives the systemic plan — which is why the treatment is coordinated between brain specialists and the oncologist managing the primary cancer.
The cells in a brain metastasis are still the original cancer type — for example, lung-cancer cells living in the brain, not new brain cells turned cancerous. That is why drugs effective against the primary cancer can also work against the brain lesions, and why up-to-date molecular and receptor testing of the primary matters before finalising treatment.
Treatment usually addresses two things at once: the lesions in the brain (with radiosurgery, surgery or whole-brain radiation) and the disease elsewhere (with systemic therapy). CION's tumour board sequences these so the brain is protected while the primary cancer keeps being treated — rather than treating the brain in isolation.
Some cancers reach the brain more often than others. If you have one of these and develop new neurological symptoms — a new headache pattern, a first-ever seizure, one-sided weakness, or vision or speech change — a brain MRI is the right next step. Each primary cancer has its own systemic options, so we cross-link the relevant hub:
Important: a new neurological symptom in someone with a known cancer is not always a metastasis — but it should be checked promptly with a brain MRI. Speak to a CION specialist to arrange a review.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
It is frightening — but it is treatable, and the options today are wider than ever. Let CION's tumour board review your scans and build a plan with you. We walk this journey with you.
There is no single "best" treatment for everyone — the plan is built around your specific situation. CION's tumour board weighs several factors before recommending an approach:
CION delivers radiation therapy, systemic therapy, imaging, molecular testing, steroid and seizure management, and supportive care directly. Where neurosurgery is needed, it is coordinated with accredited neurosurgical partners, with CION managing the overall plan.
Most plans combine more than one of these. Tap each option to read how it works and when it is used.
According to NCCN guidance, surgery or radiosurgery to the surgical cavity is preferred over whole-brain radiation for a single resected brain metastasis — and for patients with limited lesions, treating each lesion with focused radiosurgery (rather than the whole brain) is the recommended approach because it protects long-term memory and thinking.
Brain metastases care has changed quickly, so a second opinion is genuinely useful in these situations:
CION offers a free written second opinion. For more on the surgical and systemic backbone of brain-tumour care, see our brain tumor treatment overview, or return to the Brain Cancer & Tumour hub. To begin, call 18002028726 or request a review.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable before whole-brain radiation, or if your systemic therapy hasn't been updated to your latest molecular testing.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.For most people with a limited number of lesions, stereotactic radiosurgery (SRS) is now the preferred treatment. SRS delivers a high, precise dose of radiation to each metastasis in 1–5 outpatient sessions, without open surgery. Whole-brain radiation is reserved for many lesions, leptomeningeal spread, or when SRS is not feasible. Surgery is added for a large single lesion causing pressure, or when tissue is needed. Crucially, your systemic therapy for the original cancer continues, because modern targeted and immune therapies can also control disease in the brain. The right mix is decided by a tumour board, not a single specialist.
It depends on the number of lesions and your overall situation — neither is universally "better." NCCN and EANO guidance favours stereotactic radiosurgery for a limited number of metastases because it spares healthy brain and preserves memory and thinking far better than whole-brain radiation. Whole-brain radiation still has a clear role: numerous lesions, leptomeningeal disease, or rapidly progressive spread. Some centres now treat 10 or more lesions with SRS. The decision weighs lesion count and size, your performance status, and how well the primary cancer is controlled. A second opinion is reasonable if whole-brain radiation was offered without discussing SRS.
Brain metastases are a sign of advanced cancer, so "cure" is uncommon — but meaningful, durable control is realistic for many patients. Outcomes vary widely by the type of primary cancer, its molecular markers, the number of lesions, and how well disease outside the brain is controlled. With SRS plus effective systemic therapy, some lesions shrink or disappear and stay controlled for a long time. Published series report a broad survival range depending on these factors, so any number quoted to you should be a range, framed for your specific case, not a guarantee. The goal is to control disease, protect brain function and quality of life, and keep options open.
Yes — significantly. The molecular profile of the primary cancer often drives the brain plan. Some lung cancers with specific mutations respond to brain-penetrant targeted drugs. Breast cancers are treated according to receptor status (HR/HER2). Melanoma and kidney cancer brain metastases can respond to immunotherapy. That is why CION coordinates the brain plan with the medical oncologist managing the primary cancer, and why up-to-date molecular and receptor testing matters before finalising treatment.
This is a common and valid worry. The risk of memory and concentration problems is one of the main reasons modern guidelines prefer focused radiosurgery over whole-brain radiation when possible — SRS treats only the lesions and spares the rest of the brain. When whole-brain radiation is necessary, techniques such as hippocampal-avoidance planning and protective medication can reduce cognitive side effects. Steroids help control swelling and symptoms in the short term. Rehabilitation — including cognitive, speech and physiotherapy support — is part of CION's plan when needed. Ask your team specifically how your plan protects brain function.
CION delivers radiation therapy (including coordinated radiosurgery), systemic and medical therapy, imaging, molecular testing, steroid and seizure management, and supportive and rehabilitation care directly. When neurosurgery is needed — for example, removing a large single lesion causing pressure, or obtaining tissue — it is coordinated with accredited neurosurgical partners, with CION managing the overall plan and the radiation and systemic treatment that follow. This means you get a single, joined-up plan across the team rather than fragmented care.
A second opinion is especially worthwhile in three situations: if whole-brain radiation was recommended without discussing radiosurgery as an alternative; if your systemic treatment was not updated based on current molecular or receptor testing of the primary cancer; or if you were told nothing more can be done before a multidisciplinary tumour board reviewed your case. Brain metastases management has changed rapidly, and options that existed a few years ago have expanded. CION offers a free written second opinion — bring your MRI, pathology and prior treatment records. Request a review here.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.